GeNeuro Overview

  • Founded
  • 2006

Founded
  • Status
  • Public

  • Employees
  • 17

Employees
  • Stock Symbol
  • GNRO

Stock Symbol
  • Share Price
  • $2.58

  • (As of Thursday Closing)

GeNeuro General Information

Description

GeNeuro SA is a clinical-stage biopharmaceutical company. The company is developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis and other diseases associated with human endogenous retroviruses (HERV). Its lead therapeutic candidate is GNbAC1 which is a humanized monoclonal antibody that neutralizes a pathogenic HERV protein of the W family called pHERV-W env (also called MSRV env) that has been identified as a potential key factor in the onset and development of autoimmune diseases. Geographically, the group holds a presence in the region of France and Switzerland.

Contact Information

Website
www.geneuro.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
PAR
Primary Office
  • 3, Chemin du Pré-Fleuri
  • Plan-les-Ouates
  • 1228 Geneva
  • Switzerland
+41 022 000 00 00

GeNeuro Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GeNeuro Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.58 $2.57 $2.52 - $5.18 $57.2M 22.2M 2.03K -$0.38

GeNeuro Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 87,204 87,204 59,249 58,475
Revenue 0 0 0 0
EBITDA (7,708) (7,708) (9,725) (9,706)
Net Income (8,061) (8,061) (10,216) (10,591)
Total Assets 14,198 14,198 12,928 10,529
Total Debt 4,246 4,246 1,707 337
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GeNeuro Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial

GeNeuro Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
GeNeuro SA is a clinical-stage biopharmaceutical company. The company is developing a new approach to the treatment of a
Drug Discovery
Geneva, Switzerland
17 As of 2021
000.00
000000000 000.00

000000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dol
0000000000000
Gothenburg, Sweden
0 As of 0000
0000000000

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GeNeuro Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzinova Corporation Gothenburg, Sweden 0 0000000000
000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 000000000 00000
0000 Formerly VC-backed Emeryville, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00.000 000000000 00.000
You’re viewing 5 of 21 competitors. Get the full list »

GeNeuro Patents

GeNeuro Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3148582-B1 Antiretroviral drug targeting human endogenous retrovirus Active 28-May-2014 00000000000
EP-3148582-A1 Antiretroviral drug targeting human endogenous retrovirus Granted 28-May-2014 00000000000
ES-2752131-T3 Antiretroviral drug directed at human endogenous retroviruses Active 28-May-2014 00000000000
US-10894820-B2 Antiretroviral drug targeting human endogenous retrovirus Active 28-May-2014 00000000000 00
JP-2017519815-A Antiretroviral drugs targeting human endogenous retroviruses Pending 28-May-2014 C07K16/1063 0
To view GeNeuro’s complete patent history, request access »

GeNeuro Executive Team (8)

Name Title Board Seat Contact Info
Miguel Payró Chief Financial Officer
Jean-François Arrighi Ph.D Chief Development Officer
Herve Perron Ph.D Co-Founder & Chief Scientific Officer
David Leppert MD Chief Medical Officer
Jesús Martin-Garcia Chief Executive Officer
You’re viewing 5 of 8 executive team members. Get the full list »

GeNeuro Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeNeuro Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GeNeuro‘s full profile, request access.

Request a free trial